| I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $279.69M | ||||
| Company | Location | Date | Amt. (M) | Details |
|
| ||||
| AM Pharma BV | Bilthoven, the Netherlands | 8/15** | EUR0.64 (US$0.59) | AM Pharma raised US$590,000 in its first round of funding; investors included AM Pharma's management, private investors and BioPartner Startup Ventures |
| Ark Therapeutics Ltd. | London | 8/29** | #14.5 (US$21) | Ark raised US$21M in its third financing round led by BankInvest; other investors were Merlin Biosciences, Nomura International, Biofund and TVM |
| Automated Cell Inc. | Pittsburgh | 8/6 | $2.6 | Automated Cell raised $2.6M from private and institutional investors |
| Cerylid Biosciences | Melbourne, Australia | 8/23 | $9.9 | Cerylid raised $9.9M through an investment through JBWere Private Equity Fund, Rothschild BioScience Managers and CM Capital Investments |
| Chimeric Therapies Inc. | Laguna Niguel, Calif. | 8/8 | $9.7 | Chimeric raised $9.7M in a venture financing; investors included Domain Associates, Alloy Ventures, 3i Biosciences, Sofinnova Ventures, Leeway & Co., Alafi Capital and Ell & Co. |
| Eyetech | New York | 8/9 | $108.5 | Eyetech closed its Series C round, raising $108.5 million; the round was led by J.P. Morgan Partners LLC; other investors were partners and affiliates of BB Biotech AG, MPM Capital, Alta Partners, Schroder Ventures and Merrill Lynch |
| Ionix | Cambridge, | 8/8** | #8 | Ionix raised US$11.4M in its first funding led by Apax Partners and the Wellcome Trust |
| LaunchCyte | Pittsburgh | 8/8 | $0.7 | LaunchCyte closed on $700,000 of interim financing; the funds were raised in a convertible debt offering |
| MBT Munich | Munich, Germany | 8/21 | EUR30.3 | MBT completed the self-managed private placement led by Heidelberg Innovation; other investors were Deutsche Bank, Sal. Oppenheim, Deutsche Effecten, Hypo-Vereinsbank and Global Vision, as well as 3i, tbg and Global Life Science |
| Morphotek Inc. | Philadelphia | 8/13 | $10 | Morphotek raised $10M in its second round of financing led by Applied Genomic Technology Capital Funds; other investors were Burrill & Co., CB Healthcare Ventures, Tonbridge Capital and Trieste Investment Group |
| Myogen Inc. | Denver | 8/27 | $52 | Myogen completed its Series D financing round, raising $52.4M; the round was led by J.P. Morgan Partners; other investors were New Enterprise Associates, InterWest Partners, Adams Street Partners, Pacific Rim Ventures, Sequel Ltd. Partnership, CMEA Ventures and Montagu NewHall Associates |
| Q3DM Inc. | San Diego | 8/22 | $1.5 | Q3DM raised $1.5M in its Series A round led by Aztec Venture Network LLC and California Tech Coast Angel |
| TaiGen | Taiwan | 8/20 | $24 | TaiGen raised $24M in the first half of a Series A financing; MPM led the financing, and was joined by various Chinese investors (8/20) |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $21.6M | ||||
| Company | Partner | Amt. | Triggering | Details (Date) |
|
| ||||
| Alliance | Baxter Healthcare Corp. | $4 | Investment | Baxter made a $4M investment in Alliance Series F preferred stock (8/2) |
| Collateral | Schering AG | $4 | Milestone payment | Collateral received a $4M payment from Schering for the clinical advancement of Generx and Genvascor (8/13) |
| Cytoclonal | Bristol-Myers Squibb Co. | $0.6 | Milestone payment | Cytoclonal received payments totaling more than $600,000 for its work on Taxol-related projects (8/15) |
| Discovery | Techne Corp. | $3 | Investment | Techne made a $3M investment in Discovery Genomics as part of a research and license agreement to develop antibodies and immunoassays and to sell the products (8/9) |
| Exelixis Inc. | Bayer AG (Germany) | ND | Milestone payment | Exelixis achieved additional milestones through the delivery of assays (8/30) |
| Organogenesis | Novartis | $10 | Equity investment | Organogenesis is selling $10M in equity to Novartis as part of an agreement made earlier in the year (8/7) |
| Paradigm | Bayer AG (Germany) | ND | Milestone payment | Bayer installed new assays for screening in its ultra-high-throughput facility; the delivery of the assays triggered milestone payments to Paradigm (8/6) |
| Quark Biotech | Taisho | ND | Equity investment | Taisho made an equity investment in Quark as part of a Series F financing (8/22) |
| TransTech | Novo Nordisk A/S (Denmark) | ND | Equity investment | Novo Nordisk made an undisclosed equity investment in TransTech as part of a collaboration to generate clinical candidates from Novo's targets (8/15) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed | ||||
NDA = New Drug Application | ||||
AMEX = American Stock Exchange | ||||
